NLS Pharmaceutics Raises $3M in Private Placement
Ticker: NCEL · Form: 6-K · Filed: Mar 31, 2025 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Mar 31, 2025 |
| Risk Level | medium |
| Sentiment | bullish |
Sentiment: bullish
Topics: private-placement, financing, preferred-shares
TL;DR
NLS Pharma just closed a $3M private placement, selling preferred shares to 3 accredited investors.
AI Summary
On March 27, 2025, NLS Pharmaceutics Ltd. entered into a securities purchase agreement with three accredited investors for a private placement offering. The company agreed to issue and sell 1,212,122 preferred shares, par value CHF 0.03 per share, for a total of $3 million.
Why It Matters
This private placement provides NLS Pharmaceutics with $3 million in capital, which can be used to fund its ongoing operations and development of its pharmaceutical products.
Risk Assessment
Risk Level: medium — While raising capital is positive, private placements can sometimes indicate a need for immediate funding, and the terms of preferred shares can impact existing shareholders.
Key Numbers
- $3 million — Private Placement Proceeds (Capital raised to fund operations and development.)
- 1,212,122 — Preferred Shares Issued (Number of shares sold in the private placement.)
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — the company filing the report
- March 27, 2025 (date) — date of the securities purchase agreement
- $3 million (dollar_amount) — total amount raised in the private placement
- 1,212,122 (number) — number of preferred shares issued
- CHF 0.03 (dollar_amount) — par value per preferred share
FAQ
What is the total amount NLS Pharmaceutics raised in this private placement?
NLS Pharmaceutics raised a total of $3 million in this private placement.
When was the securities purchase agreement signed?
The securities purchase agreement was entered into on March 27, 2025.
How many preferred shares did NLS Pharmaceutics agree to issue?
The company agreed to issue 1,212,122 preferred shares.
What is the par value of the preferred shares issued?
The par value of the preferred shares is CHF 0.03 per share.
How many accredited investors participated in the private placement?
Three accredited investors participated in the private placement.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 31, 2025 regarding NLS Pharmaceutics Ltd. (NCEL).